Soliris Intravenous, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS).
In the last several years, Asia-Pacific market of Soliris Intravenous developed rapidly.Japan is the largest consumption place. Market competition is not intense.The FDA will not approve biosimilar applications for Soliris Intravenous before 16 March 2019; there is an ongoing debate over the length of exclusivity periods.

The global Soliris Intravenous market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Soliris Intravenous volume and value at global level, regional level and company level. From a global perspective, this report represents overall Soliris Intravenous market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Soliris Intravenous in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Soliris Intravenous manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Alexion
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Plasma Exchange
Plasma Infusion

Segment by Application
PNH
AHUS
Other